Evaluation of interleukin-1. Receptor antagonist (IL-1RA) and tumor necrosis factor binding protein (TNF-BP) in a rodent abscess model of host resistance

Immunopharmacology and Immunotoxicology

Volumn 18, Issue 3, 1996, Pages 397-419

  Colagiovanni, D B ^a   Shopp, G M ^a,b  

^a AMGEN INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; DEXAMETHASONE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; CARRIER PROTEIN; INTERLEUKIN 1 RECEPTOR; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR BINDING PROTEIN 1; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR-BINDING PROTEIN-1; SIALOGLYCOPROTEIN; TUMOR NECROSIS FACTOR DECOY RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ABSCESS; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; FEMALE; HOST RESISTANCE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS AUREUS; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; INNATE IMMUNITY; SPRAGUE DAWLEY RAT;

ANIMALIA; BACTERIA (MICROORGANISMS); RODENTIA; STAPHYLOCOCCUS AUREUS;

ABSCESS; ANIMALS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNITY, NATURAL; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, INTERLEUKIN-1; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029658581     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.3109/08923979609052743     Document Type: Article

References (29)

1. Lebrec, H., Blot, C., Pequet, S., Roger, R., Bohoun, C. and Pallardy, M., Immunotoxicologial Investigation Using Pharmaceutical Drugs: In Vivo Evaluation of Immune Function, FAT, 23: p. 159, 1994.
2. House, R. V., Thomas, P. T. and Bhargava, H. N., Selective Modulation of Immune Function Resulting from In Vitro Exposure to Methylenedioxymethamphetamine (ectasy), Toxicology, 96: p. 59, 1995.
3. Weissinger, J., Nonclinical Pharmacologic and Toxicologic Considerations for Evaluating Biologic Products, Regulatory Toxicology and pharmacology, 10: p. 255, 1989.
4. Dinarello, C. A., Biology of Interleukin-1, FASEB J., 2: p. 108, 1988.
5. Sharar, S. R., Winn, R. K., Murry, C. E., Harlan, J. M. and Rice, C. L., A CD18 Monoclonal Antibody Increases the Incidence and Severity of Subcutaneous Abscess Formation after High-Dose Staphylococcus aureus Injection in Rabbits, Surgery, 110: p. 213, 1991.
6. Duff, G. W., in Clinical Applications of Cytokines, J. Oppenheim, Rossio, and Gearing, Editors. 1993, Oxford University Press: New York, p. 263, ch. 15.
7. Dinarello, C. A., Role of Interleukin-1 in Infectious Diseases, Immunol. Rev, 127: p. 119, 1992.
8. Elliott, MJ., Maini, R.N., Feldmann, M., Kalden, J.R., Antoni, C., Smolen, J.S., Leeb, B., Breedveld, F.C., Macfarlane, J.D., Bijl, H., Woody, J.N. Randomised Double-Blind Comparison of Chimeric Monoclonal Antibody to Tumor Necrois Factor-α. (cA2) Versus Placebo in Rheumatoid Arthritis. The Lancet, 344: p. 1105, 1994.
9. Russell, D.A., Tucker, K.K., Chinookoswong, N., Thompson, R.C., Kohno, T. Combined Inhibition of Interleukin-1 and Tumor Necrosis Factor in Rodent Endotoxemia: Improved Survival and Organ Function. J. Inf. Dis, 171: p. 1528, 1995.
10. Espat, N.J., Cendan, J.C., Beierle, E.A., Auffenberg, T.A., Rosenberg, J., Russell, D., Kenney, J.S., Fischr, E., Montegut, W., Lowry, S.F., Copeland, E.M., Moldawer, L.L. PEG-BP-30 Monotherapy Attenuates the Cytokine-Mediated Inflammatory Cascade in Baboon Escherichia coli Septic Shock. J. Surg. Res., 59: p. 153, 1995.
11. Faherty, D. A., Claudy, V., Plocinski, J. M., Kaffka, K., Kilian, P., Thompson, R. C. and Benjamin, W. R., Failure of IL-1 Receptor antagonist and Monoclonal Anti-IL-1 Receptor Antibody to Inhibit Antigen-Specific Immune Responses In Vivo, JI, 148: p. 766, 1992.
12. Granowitz, E. V., Clark, B. D., Mancilla, J. and Dinarello, C. A., Interleukin-1 Receptor Antagonist Competitively Inhibits the Binding of Interleukin-1 to the Type II Interleukin-1 Receptor, JBC, 266: p. 14147, 1991.
13. Carter, D. B., Deibel, M.R., Dunn, C.J., Tomich, C.S., Laborde, A.L., Slighton, J.L., Berger, A.E., Bienkowski, M.J., Sun, F.F., McEwan, R.N., et al. Purification, Cloning, Expression, and Biological Characterization of an Interleukin-1 Receptor Antagonist Protein. Nature, 344: p. 633, 1990.
14. DuPasquier, L., in Fundamental Immunology, W.E. Paul, Editor. 1993, Raven Press, p. 199.
15. Beutler, B., Milsark, I. W. and Cerami, A., Passive Immunization against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin. Science, 229: p. 869, 1985.
16. Havell, E. A., Moldawer, L., L., Helfgott, D., Kilian, P., L. and Sehgal, P., B., Type I IL-1 Receptor Blockade Exacerbates Murine Listeriosis, J. Immunology, 148: p. 1486, 1992.
17. Nakane, A., Minagawa, T. and Kato, L., Endogenous Tumor Necrosis Factor (Cachectin) is Essential to Host Resistance against Listeria Monocytogenes Infection. Infection and Immunology, 56: p. 2563, 1988.
18. Hale, K.K., Smith, G.G., Baker, S.L., Vanderslice, R.W., Squires, C.H., Gleason, T.M., Tucker, K.K., Kohno, T., Russell, D.A. Multifunctional Regulation of the Biological Effects of TNF-α by the Soluble Type I and Type II TNF Receptors. Cytokine, 7, p. 26, 1995.
19. Citak, M.S., Cue, J.I., Peyton, J.C., Malangoni, M.A., The Critical Relationship of Antibiotic Dose and Bacterial Contamination in Experimental Infection , Journal of Surgical Research, 52, 1992, p. 127.
20. Pun, Y. L. W., Barraclough, D. R. E. and Muirden, K. D., Leg Ulcers in Rheumatoid Arthritis, The Medical Journal of Australia, 153: p. 585, 1990.
21. van Furth, R., van Zwet, T. L., Buisman, A. M. and van Dissel, J. T., Anti-Tumor Necrosis Factor Antibodies Inhibit the Influx of Granulocytes and Monocytes into an Inflammatory Exudate and Enhance the Growth of Listeria monocytogenes in Various Organs, JID, 170: p. 234, 1994.
22. Hannum, C.H., Wilcox, C.J., Arend, W.P. Primary Structure and Functional Expression from Complementary DNA of a Human Interleukin-1 Receptor Antagonist. Nature, 343: p. 336, 1990.
23. Bomberger, C.E. & Haar, J.L. Dexamethasone and Hydrocortisone Enhance the in vitro Migration of Prethymic Stem Cells to Thymus Supernatant. Thymus, 20: p. 89, 1992.
24. Renzi, P.M., Livenstein, R., Martin, J.G. Effect of Dexamethasone on Airway Inflammation and Responsiveness After Antigen Challenge of the Rat. Am. Rev. Respir. Dis. 148: p. 932, 1993.
25. Rinehart, J., Delamater, E. W., Keville, L. and Measel, J., Corticosteroid Modulation of IL-1 Hematopoietic Effects and Toxicity in a Murine System, Blood, 84: p. 1457 , 1994.
26. Luscinskas, F. W., Cybulsky, M. I., Kiely, J.-M., Peckins, C. S., David, V. M. and Gimbrone, M. A., Cytokine-activated Human Endothelial Monolayers Support Enhanced Neutrophil Transmigration via a Mechanism Involving Both Endothelial-leukocyte Adhesion Molecule-1 and Intercellular Adhesion Molecule-1, JI, 146: p. 1617, 1991.
27. Tracey, K. J., TNF and Mae West or: Death from too Much of a Good Thing, The Lancet, 345: p. 75, 1995.
28. Eisenberg, S. P., Thompson, R. C. and Cox, G. N. an interleukin-1 inhibitor (IL-1i) blocks IL-1 induced adhesion of neutrophils to endothelial cells, in Second International workshop on cytokines. 1992 (abstract # 106).
29. Sharer, S.R., Sasaki, S.S., Flaherty, L.C., Paulson, J.C., Harlan, J.M., and Winn R.K. P-Selectin Blockade does not Impair Leukocyte Host Defense against Bacterial Peritonitis and Soft Tissue Infection in Rabbits, J. Immunology. 9; p. 4982, 1993.